Attendee search 

Berkley Life Sciences focuses on providing quality and competitively-priced liability insurance products that help protect the futures of innovators in the Life Sciences field.

As a member company of the W. R. Berkley Corporation, we underwrite on behalf of some of the best insurance companies around, including:

• Gemini Insurance Company
  • A.M. Best Financial Strength Rating of A+ (Superior) with a Financial Size Category XV ($2 billion or more), and an A+ (Strong) Financial Strength Rating from Standard & Poor's
• Nautilus Insurance Company
  • A.M Best Financial Strength Rating of A+ (Superior) with a Financial Size Category X
• StarNet Insurance Company
  • A.M Best Financial Strength Rating of A+ (Superior) with a Financial Size Category XV
• Berkley National Insurance Company
  • A.M Best Financial Strength Rating of A+ (Superior) with a Financial Size Category XV
• Berkley Regional Insurance Company
  • A.M Best Financial Strength Rating of A+ (Superior) with a Financial Size Category X

We also have the in-house claims management and Life Sciences experience to address claims of all types – whether made in the United States or internationally. Quality control measures designed specifically for the Life Sciences field by our experts are integrated into the claims process to ensure compliance with best practices.

Where necessary, we also have access to a worldwide network of Life Sciences professionals. This combination of in-house expertise and available outside resources enables us to formulate an effective strategy – whether it involves settlement or defending a case to conclusion.

UB is a premier, research-intensive public university and a member of the Association of American Universities. As the largest, most comprehensive institution in the 64-campus State University of New York system, our research, creative activity and people positively impact the world. 

As a SUNY Distinguished Professor and Associate Director of the New York State Center of Excellence in Bioinformatics and Life Sciences, Dr. Morse has extensive experience in coordinating and governing multidisciplinary research efforts involving health information technology to improve patient safety. Dr. Morse also directs the Empire State Patient Safety Assurance Network, an AHRQ-designated, federally certified Patient Safety Organization and has led the UB 2020 effort to develop a model for statewide medication management programs in partnership with the NYS Department of Health Patient Safety Center. Dr. Morse has also worked with UB to establish the ESPSAN as a component of the UB 2020 planning process, a program that includes the School of Pharmacy and Pharmaceutical Sciences, Nursing, Medicine and Public Health. He also developed the UB Pharmacotherapy Information Center (PIC) and has led an effort to develop model medication management programs in Western New York and established the regional HIV Adherence-Pharmacology Program. Dr. Morse is also Co-Director of the UNYTE Translational Research Network of the University of Rochester CTSI, regional network composed of 18 academic and research institutions. In addition, Dr. Morse is the Director of the Translational Pharmacology Research Core in the New York State Center of Excellence in Bioinformatics and Life Sciences. Dr. Morse also holds appointments as a Professor in the Department of Pharmacy Practice, and Research Professor of Medicine and Pediatrics, at the University at Buffalo. Dr. Morse was previously the Associate Dean of Clinical and Translational Research in the School of Pharmacy and Pharmaceutical Sciences at the University at Buffalo.

Based on a fifteen years experience leveraging innovative R & D solutions geared towards chronic disease patients.

Dedicated to selected chronic diseases leading to an efficient management of the healthcare costs, enhanced patient benefits and improved quality of life.

A strong value-added connected health information system and a proven expertise in home healthcare through a series of programs closely connecting patients with health professionals.

An international multidisciplinary team with a proven record in the areas of healthcare, patient care, connected and social computer networks, design and ergonomics and health policy issues.

First transatlantic organization in Applied Telemedicine, offering cost efficient solutions to healthcare payers.

An expertise and proven experience implemented in Europe and complying with stringent privacy and personal information laws for personal health information at the payer, provider and patient level.

TechnoVax is a privately held near-clinical-stage biotechnology company based in Tarrytown, NY specializing in viral vaccine development. Our mission is to create and advance towards the market safe, unique and novel vaccine technologies with no current alternatives that will revolutionize the way vaccines are developed, distributed and administered. 

TechnoVax has developed a next-generation technology-platform based on Virus-Like Particles (VLP) that greatly enhances and facilitates the development and production of a limitless range of vaccines targeting the prevention of respiratory diseases as well as hemorrhagic fevers, immunodeficiency and cancers. The industry strongly believes that VLP based vaccines is the technology of the future! 

Our vaccines pipeline has been rapidly approaching the clinical phases with 3 main candidates: 
- A Universal flu vaccine that will eliminate the need for annual flu vaccination and will protect faster and better against future pandemic strains; 
- An Inhaled Powder flu vaccine that eliminates the need for cold chain storage and distribution and could be self-administered: a greatly needed solution for the developing world; 
- An RSV vaccine to protect against one of the leading causes of infant and elderly hospitalizations and often results in fatalities with the elderly. 

We have received over $5.0 million in non-dilutive funding. We are actively pursuing strategic partnerships and are seeking funding to start human testing.

A clinical research provider that conducts clinical research for pharmaceutical and biotechnological companies as well as government sponsored trials. We also facilitate training programs for clinical research practitioners and site preparation for studies.

We also aim to help clinical research facilities and professionals conduct clinical trials following GCP/ICH. By doing so we believe will be beneficial to pharmaceutical companies as it would allow for clinical trials to run smoother and more efficiently. It will also help subjects get quality service during the clinical studies.

Donec sodales a quam in imperdiet. Aliquam massa libero, malesuada nec interdum sit amet, gravida quis nibh. Praesent facilisis tristique egestas. Curabitur vitae metus vitae libero iaculis suscipit. Nullam non velit metus. Curabitur at euismod felis. Aenean viverra sem sit amet ante bibendum, sit amet vehicula eros dapibus.

Exsight Capital is a venture capital firm specializing in early-stage impact investments in innovative ophthalmic diagnostic and treatment solutions.

Founded in 1852, The Mount Sinai Hospital is a 1,171-bed, tertiary-care teaching facility acclaimed internationally for excellence in clinical care.

U.S. News & World Report ranks The Mount Sinai Hospital among the top hospitals nationwide. Mount Sinai also ranks in several specialties and is top 10 in three of those: Geriatrics (#3), Cardiology and Heart Surgery (#7), and Gastroenterology (#8).

Allovate Therapeutics is a specialty pharmaceutical company dedicated to simplifying allergy treatment. Allovate’s approach to allergy immunotherapy is built around the Allerdent® therapeutic platform. 

Allerdent® is formulated as an easy-to-use, customizable toothpaste that incorporates and stabilizes the immunotherapeutic agents used to treat food and respiratory allergies. It conveniently integrates immunotherapy into an allergy sufferer’s everyday brushing routine. Allerdent® makes tackling allergies as simple as brushing your teeth. 

Clinical investigations led by Allovate Therapeutics are developing this platform for the treatment of food allergies. Allerdent® offers the potential of a long-term solution for the 15 million Americans who have food allergies. 

Allergy immunotherapy is the only disease-modifying allergy treatment, demonstrated to be effective in over 100 years of clinical use. This approach changes how the body responds to allergens over time by exposing the immune system to purified allergen extracts in a controlled way over a period of time. Our approach, oral mucosal immunotherapy (OMIT), is designed to overcome the challenges of existing approaches to immunotherapy. OMIT delivers immunotherapeutic agents to the areas of the oral cavity with the greatest potential for reducing allergy symptoms and a lower likelihood of side effects.

The Icahn School of Medicine at Mount Sinai is an international leader in medical and scientific training, biomedical research, and patient care. It is the medical school for the Mount Sinai Health System, which includes seven hospital campuses, and has more than 5,000 faculty and nearly 2,000 students, residents and fellows. Our unwavering pursuit of intellectual exchange, breakthrough research, and multidisciplinary teamwork propels us ever forward in biomedical discoveries and advances. We pursue ideas that often challenge conventional wisdom to revolutionize the practice of medicine and produce dramatically better outcomes for patients. We make big, bold bets by investing in radical free thinkers and technology at the cutting edge.

ABOUT US: 

Alpha Bronze is a leading provider of investor relations and strategic corporate communications. We have been working with US and non-US private and public companies to build their profiles within the investment community.

Based in New York, Alpha Bronze's single core competency is:

• the development and execution of tailored, strategic investor communication programs.

Our approach is straightforward: by thoroughly and by leveraging our expertise and knowledge of the "Street", we help our clients:

• develop clear and consistent key messages,
• raise their awareness and profiles in the global investment community and,
• ulimately maximize the market value of their stock and company.